Biology, Loops, and Decision-Grade Trust

Click here to watch a video of this episode. In drug development, go/no-go decisions concentrate translational risk and expose real consequences. When AI or digital biomarkers influence that call, decision-grade evidence in a regulated environment is not optional. This episode sits in the moment every executive recognizes: the slide is on the screen and someone asks, “Do we advance?” Here’s the tension. We love the word validated, but what happens when the next dataset disagrees? We introduce a practical discipline we call the decision warranty: clear scope, clear evidence chain, clear boundaries, and explicit triggers for pause, rerun, or escalation. Someone has to own that call. Takeaway: if you cannot write the stop triggers and the decision owner on one page, do not let the tool move the decision. (00:00) - Forward Looking Themes for 2025 (01:00) - Reproducibility Crisis and Foundational Biology (02:00) - Digital Measures and Preventive Health (03:00) - Multimodal AI and Foundation Models (06:00) - Closed Loop Data Generation and Innovation (09:00) - Decision Making as a Core Capability (13:00) - Human in the Loop and Accountability (16:00) - Micro Physiological Endpoints and Decision Use Limits (21:00) - Democratizing Data and Model Access (24:00) - Biology as Foundation for Modeling Systems (28:00) - Opportunity, Effort, and Due Diligence  If you liked this episode, steal the monthly cheat sheet at Innovation2Impact Newsletter (we do the digging, you keep the credit).